Proactiveinvestors United Kingdom Polarean Imaging PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Polarean Imaging PLC RSS feed en Sun, 16 Jun 2019 04:01:05 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Investor Symposium presentations available online ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190613170212_14110465/ Thu, 13 Jun 2019 17:02:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190613170212_14110465/ <![CDATA[Media files - Polarean Imaging updates on clinical trials ahead of investor symposium ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13707/polarean-imaging-updates-on-clinical-trials-ahead-of-investor-symposium-13707.html Wed, 12 Jun 2019 10:04:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13707/polarean-imaging-updates-on-clinical-trials-ahead-of-investor-symposium-13707.html <![CDATA[News - Polarean Imaging on schedule for US launch of lung function scanner ]]> https://www.proactiveinvestors.co.uk/companies/news/221870/polarean-imaging-on-schedule-for-us-launch-of-lung-function-scanner-221870.html MRI scans generally aren’t very useful in assessing lung function, but Polarean Imaging PLC (LON:POLX) is trying to change that.

The company has developed a drug-device combination which uses hyperpolarised 129-Xenon gas MRI. By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Polarean, which is looking to sell the gas, the instrument which polarises the gas, and an associated quality assurance device, kicked off a trial of the technology last summer in two sites: Duke University and the University of Virginia and at the University of Cincinnati in June.

The trial is a 'head-to-head' non-inferiority trial testing 129Xe MRI against 133-Xenon (133Xe) scintigraphy.

In the trial, the firm will be evaluating two patient populations - candidate patients for lung lobe resection, and lung transplant procedures - numbering 80 patients in total.

If approved by the FDA, the commercial launch is expected during the second half of 2020.

What the boss says - Richard Hullihen, chief executive:

“Enrolment for the lung transplant pathway is now nearing completion and I look forward to providing shareholders with further updates regarding our clinical trials as soon as practicable."

Inflexion points: Completion of enrolment of patients Trial data and FDA decision Commercial launch in 2020 Revenues in half year to June 2018 were US$1mln with a loss of US$2.8mln Raised US$4mln in December. At 16p, Polarean is valued at £16mln Blue sky:

Pulmonary medicine and lung functions have been left behind in the diagnostic revolution that has seen MRI and CT scanning become the norm in oncology, for example.

COPD, IPF, emphysema, cystic fibrosis can all take years before the real cause of the problem is apparent and by that stage it is often too late.

“The annual burden of pulmonary disease in the US is estimated to be over US$150bn and Polarean expects over US$500mln in system sales just to top-tier institutes,” broker Northland said last year.

]]>
Tue, 11 Jun 2019 10:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221870/polarean-imaging-on-schedule-for-us-launch-of-lung-function-scanner-221870.html
<![CDATA[News - Polarean Imaging begins enrolling at third site for clinical trials of MRI lung scan ]]> https://www.proactiveinvestors.co.uk/companies/news/221848/polarean-imaging-begins-enrolling-at-third-site-for-clinical-trials-of-mri-lung-scan-221848.html Polarean Imaging PLC (LON:POLX) confirmed that enrolment of the final few patients for clinical testing of its drug-device combination for MRI lung scans will soon begin at a third trial site.

The trials, where the company is looking to prove that holding a breath of inert, hyperpolarised 129-Xenon gas while undertaking an MRI can provide clearer images for doctors, have so far enrolled 85.4% of the required number of patients in the lung transplant pathway and 62.5% for the lung resection pathway. This is up from 80% and 50% in mid-May.

As indicated last month, a third trial site at the University of Cincinnati will now be added to improve the rate of enrolment for the lung resection pathway, with the first patient expected to be enrolled at UC shortly.

Polarean said the addition of the third trial site will push back completion of enrolment into the third quarter of the 2019 but directors remain confident that the company is on track to meet its current timetable for the regulatory submission of a new drug application (NDA) with the US Food and Drug Administration (FDA).

Chief executive Richard Hullihen said: "We are pleased to confirm that Polarean will be activating the additional trial site at UC this month, to help ensure a timely completion of the enrolment process for the lung resection pathway. 

“Enrolment for the lung transplant pathway is now nearing completion and I look forward to providing shareholders with further updates regarding our clinical trials as soon as practicable."

Polarean, which is looking to market a single product the combined the 129-Xenon gas, the instrument which polarises the gas, and an associated quality assurance device, started trials of the technology last summer in two sites, Duke University and the University of Virginia.

If approved by the FDA, commercial launch is expected to occur during the second half of 2020, as previously indicated.

]]>
Tue, 11 Jun 2019 07:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221848/polarean-imaging-begins-enrolling-at-third-site-for-clinical-trials-of-mri-lung-scan-221848.html
<![CDATA[RNS press release - Phase III Clinical Trials - Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190611070008_14105685/ Tue, 11 Jun 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190611070008_14105685/ <![CDATA[News - Polarean Imaging receives system order from Canadian children’s hospital ]]> https://www.proactiveinvestors.co.uk/companies/news/221533/polarean-imaging-receives-system-order-from-canadian-childrens-hospital-221533.html Polarean Imaging PLC (LON:POLX) has received a research unit order for its 9820 Xenon Polariser system from The Hospital for Sick Children (SickKids) in Toronto.

The order for the 9820, which provides hyperpolarised Xenon for use in magnetic resonance studies, will, once received, take the total number of polarisers installed or on order to 24.

READ: Polarean Imaging to receive third tranche of research grant

The system will also help to expand SickKids' ongoing paediatric research programme using hyperpolarised gas imaging.

The hospital currently has an earlier model of Polarean’s polariser, which has recently been upgraded.

"We are very happy to extend our long-standing relationship with SickKids Hospital in Toronto who work tirelessly on the paediatric applications of hyperpolarised xenon imaging for this important patient population", said Richard Hullihen, Polarean’s chief executive.

In early trading on Wednesday, Polarean's shares were steady at 15p.

]]>
Wed, 05 Jun 2019 08:25:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221533/polarean-imaging-receives-system-order-from-canadian-childrens-hospital-221533.html
<![CDATA[RNS press release - New System Order ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190605070013_14098757/ Wed, 05 Jun 2019 07:00:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190605070013_14098757/ <![CDATA[RNS press release - Grant of Share Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190523152608_14085689/ Thu, 23 May 2019 15:26:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190523152608_14085689/ <![CDATA[RNS press release - London Investor Symposium ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190523070010_14084409/ Thu, 23 May 2019 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190523070010_14084409/ <![CDATA[News - Polarean Imaging to receive third tranche of research grant ]]> https://www.proactiveinvestors.co.uk/companies/news/220673/polarean-imaging-to-receive-third-tranche-of-research-grant-220673.html Polarean Imaging PLC (LON:POLX), the medical imaging technology company, is set to receive another US$1mln through a research grant.

The company said it will receive the third tranche of US$1mln as part of its US$3mln Small Business Innovation Research grant.

READ Polarean adds third trial site to late-stage study of its lung MRI scan technology

The funds will be used to continue a Phase III trial evaluating the use of 129 Xe magnetic resonance imaging scanning for children being treated for cystic fibrosis (CF).

"Year three of this NIH [US National Institutes of Health] proposal will allow us to fully validate the hypothesis that hyperpolarised Xe MRI is sensitive to mild lung-function declines associated with CF in children. We anticipate that this work programme will be a launching point for future studies that will use the technique as a primary or secondary endpoint to demonstrate efficacy of therapeutic agents in CF and other obstructive lung diseases,” said Jason Woods of the Cincinnati Children’s Hospital Medical Center – one of Polarean’s long-standing collaborators.

Richard Hullihen, the chief executive officer of Polarean, said there are several new drug therapies under development by manufacturers and a key element in expediting the development and commercialisation process is having quantitative, reproducible, non-invasive imaging-based measures of a biological state (i.e. biomarkers).

“These biomarkers could reduce the cost of trials and maximise the outcome and proof of cost efficacy in this critical patient population. Achieving these milestones may facilitate expansion of the developed techniques to other members of the Xenon MRI Trials Consortium for multi-centre trials. We believe the applications being developed in CF could further expand the use of 129-Xe imaging as we continue to progress our own Phase III Clinical Trials, which are testing our drug-device combination for the evaluation of pulmonary ventilation," Hullihen said.

Shares in Polarean were up 2.4% at 16.125p in early trading.


 

]]>
Tue, 21 May 2019 09:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220673/polarean-imaging-to-receive-third-tranche-of-research-grant-220673.html
<![CDATA[RNS press release - 3rd tranche of $3m pediatric study grant confirmed ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190521070021_14080967/ Tue, 21 May 2019 07:00:21 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190521070021_14080967/ <![CDATA[News - Polarean adds third trial site to late-stage study of its lung MRI scan technology ]]> https://www.proactiveinvestors.co.uk/companies/news/220102/polarean-adds-third-trial-site-to-late-stage-study-of-its-lung-mri-scan-technology-220102.html Polarean Imaging Plc (LON:POLX) is adding a third clinical trial site to the phase III study of its hyperpolarised 129-Xenon (129Xe) gas magnetic resonance imaging (MRI) technology.

MRI scans generally aren't much use when assessing lung function, but Polarean has developed a way in which a small amount of inert gas can change that.

READ: Polarean Imaging appoints former CFO of cancer therapeutics firm as new finance boss

By inhaling and holding a small amount of the 129Xe gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Polarean, which is looking to sell the gas, the instrument which polarises the gas, and an associated quality assurance device, kicked off a trial of the technology last summer in two sites: Duke University and the University of Virginia.

Enrolment for the trials has now passed 80% (39 of 48 patients) in the lung transplant pathway and 50% (16 of 32) in the lung resection pathway.

Third site added

To improve the rate of enrolment for the lung resection pathway in order to align the pathway completion dates, and because neither site should enrol more than 65% of patients in a pathway, Polarean plans to add a third trial site at the University of Cincinnati, which is already one of its key clinical collaborators.

It is expected that UC will start enrolling patients next month (June), and bosses are confident it will not affect the regulatory submission timetable, with commercial launch still being targeted for the second half of 2020.

Boss content

“We are satisfied with the progress of our clinical trials to date,” said chief executive Richard Hullihen.

“We are pleased to be adding an additional trial site at UC to improve the enrolment process for the lung resection pathway, thereby extending our collaboration with UC.”

]]>
Mon, 13 May 2019 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220102/polarean-adds-third-trial-site-to-late-stage-study-of-its-lung-mri-scan-technology-220102.html
<![CDATA[RNS press release - Clinical trial update ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190513070005_14070639/ Mon, 13 May 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190513070005_14070639/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190430070006_14056274/ Tue, 30 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190430070006_14056274/ <![CDATA[News - Polarean Imaging appoints former CFO of cancer therapeutics firm as new finance boss ]]> https://www.proactiveinvestors.co.uk/companies/news/219239/polarean-imaging-appoints-former-cfo-of-cancer-therapeutics-firm-as-new-finance-boss-219239.html Polarean Imaging Plc (LON:POLX) has appointed the former chief financial officer (CFO) of an oncology therapeutics firm as its new finance boss.

The medical imaging firm said Charles (Chuck) Osborne, Jr, who joins the company from Innocrin Pharmaceuticals Inc, would begin the role with immediate effect and will replace outgoing CFO Bill Patrick, who would take up the post of financial controller at Polarean Inc, the group’s subsidiary.

READ: Polarean Imaging signs deal with University of British Colombia

Prior to his role at Innocrin, Osborne was CFO of anti-infective therapy group Scynexis Inc (NASDAQ:SCYX).

Richard Hullihen, Polarean’s chief executive, said Osborne’s “previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function”.

]]>
Mon, 29 Apr 2019 08:12:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219239/polarean-imaging-appoints-former-cfo-of-cancer-therapeutics-firm-as-new-finance-boss-219239.html
<![CDATA[RNS press release - Appointment of Chief Financial Officer ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190429070019_14054579/ Mon, 29 Apr 2019 07:00:19 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190429070019_14054579/ <![CDATA[RNS press release - Exercise of Warrants ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190402070003_14024491/ Tue, 02 Apr 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190402070003_14024491/ <![CDATA[RNS press release - Amphion Innovations - Pledge of Polarean shares ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190401070008_14022541/ Mon, 01 Apr 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190401070008_14022541/ <![CDATA[News - Polarean Imaging signs deal with University of British Colombia ]]> https://www.proactiveinvestors.co.uk/companies/news/214698/polarean-imaging-signs-deal-with-university-of-british-colombia-214698.html Polarean Imaging Plc (LON:POLX), the medical imaging technology company, said the University of British Columbia (UBC) is acquiring one of the company’s polarizer systems.

No financial details were mentioned, but the Polarean release said UBC has received support from the Canada Foundation for Innovation.

The company’s chief executive, Richard Hullihen, said: "We are excited to welcome Doctors Sin and Leipsic and the staff of UBC to our expanding base of collaborative researchers and look forward to assisting them in achieving the goals of their research programme.

“UBC has a long history and pioneering reputation in the field of medical imaging research and I look forward to providing further updates regarding our collaboration with UBC as appropriate.”

]]>
Fri, 15 Feb 2019 08:07:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214698/polarean-imaging-signs-deal-with-university-of-british-colombia-214698.html
<![CDATA[RNS press release - New System Order ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190215070003_13970330/ Fri, 15 Feb 2019 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190215070003_13970330/ <![CDATA[RNS press release - Appointment of Nominated Adviser and Broker ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190124070008_13944883/ Thu, 24 Jan 2019 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190124070008_13944883/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190121153640_13941698/ Mon, 21 Jan 2019 15:36:40 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190121153640_13941698/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190103070011_13922060/ Thu, 03 Jan 2019 07:00:11 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20190103070011_13922060/ <![CDATA[RNS press release - Result of General Meeting and Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181228145230_13918414/ Fri, 28 Dec 2018 14:52:30 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181228145230_13918414/ <![CDATA[Media files - Polarean has submission for US approval and completion of trials 'clearly in its sights' ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11639/polarean-has-submission-for-us-approval-and-completion-of-trials--clearly-in-its-sights--11639.html Mon, 17 Dec 2018 14:47:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11639/polarean-has-submission-for-us-approval-and-completion-of-trials--clearly-in-its-sights--11639.html <![CDATA[News - City broker reckons Polarean shares are worth three times their current value ]]> https://www.proactiveinvestors.co.uk/companies/news/210960/city-broker-reckons-polarean-shares-are-worth-three-times-their-current-value-210960.html Broker Northland Capital has initiated coverage of shares in the medical devices specialist Polarean Imaging PLC (LON:POLX) with a 46p a share valuation.

The Northland target, derived using discounted cash flow analysis, is roughly triple the current price.

The company is currently running two phase III trials for its drug-device platforms, which analyst Vadim Alexandre believes will propel it into the lucrative pulmonary disease market, which is estimated to be worth US$150bn in the US alone.

“Polarean expects over US$500mln in system sales just to top-tier institutes,” said Alexandre in a note to clients.

The shares were off 15% in early trade after it said it had conditionally raised US$4mln from investors at a price of 14p.

Those who took part in the fundraiser will no doubt be keenly interested in the Northland analysis, which speaks to the significant potential of Polarean, which listed on AIM in March.

]]>
Tue, 11 Dec 2018 11:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210960/city-broker-reckons-polarean-shares-are-worth-three-times-their-current-value-210960.html
<![CDATA[RNS press release - Investment in Polarean & Loan Facility Repayment ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181211070502_13898791/ Tue, 11 Dec 2018 07:05:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181211070502_13898791/ <![CDATA[RNS press release - Conditional Fundraise to raise US$4 million ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181211070012_13898707/ Tue, 11 Dec 2018 07:00:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181211070012_13898707/ <![CDATA[RNS press release - Licencing Agreement with Duke University ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181113070012_13864237/ Tue, 13 Nov 2018 07:00:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181113070012_13864237/ <![CDATA[RNS press release - Company update ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181106070007_13855910/ Tue, 06 Nov 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181106070007_13855910/ <![CDATA[RNS press release - Nominated Adviser Status ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181105070006_13854166/ Mon, 05 Nov 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181105070006_13854166/ <![CDATA[RNS press release - Delivery of Xenon Polariser ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181003070002_13813998/ Wed, 03 Oct 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20181003070002_13813998/ <![CDATA[RNS press release - FIRST PATIENT IN PHASE III FDA CLINICAL TRIAL ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180823070005_13765287/ Thu, 23 Aug 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180823070005_13765287/ <![CDATA[RNS press release - Half-year Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180822070005_13763746/ Wed, 22 Aug 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180822070005_13763746/ <![CDATA[RNS press release - Company update ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180727070005_13733457/ Fri, 27 Jul 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180727070005_13733457/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180718142845_13722858/ Wed, 18 Jul 2018 14:28:45 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180718142845_13722858/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180717144952_13721153/ Tue, 17 Jul 2018 14:49:52 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180717144952_13721153/ <![CDATA[RNS press release - Result of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180710152249_13712658/ Tue, 10 Jul 2018 15:22:49 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180710152249_13712658/ <![CDATA[RNS press release - Proposed Placing to raise a minimum of £0.78m ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180709144139_13710871/ Mon, 09 Jul 2018 14:41:39 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180709144139_13710871/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180621101223_13688499/ Thu, 21 Jun 2018 10:12:23 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180621101223_13688499/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619164021_13685912/ Tue, 19 Jun 2018 16:40:21 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619164021_13685912/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619163514_13685898/ Tue, 19 Jun 2018 16:35:14 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619163514_13685898/ <![CDATA[RNS press release - Investor Symposium ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619070012_13684493/ Tue, 19 Jun 2018 07:00:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180619070012_13684493/ <![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180613070005_13677192/ Wed, 13 Jun 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180613070005_13677192/ <![CDATA[RNS press release - Delivery of Xenon Polariser ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180606070007_13668337/ Wed, 06 Jun 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180606070007_13668337/ <![CDATA[RNS press release - London Investor Symposium ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180531070007_13660764/ Thu, 31 May 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180531070007_13660764/ <![CDATA[RNS press release - Delivery of Xenon Polariser ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180522070004_13649566/ Tue, 22 May 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180522070004_13649566/ <![CDATA[RNS press release - Grant of Share Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180420070004_13611910/ Fri, 20 Apr 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180420070004_13611910/ <![CDATA[RNS press release - Polarean technology used in severe asthma study ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180417070008_13606709/ Tue, 17 Apr 2018 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180417070008_13606709/ <![CDATA[RNS press release - AIM Admission & First Day of Dealings ]]> https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180329070012_13586019/ Thu, 29 Mar 2018 07:00:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16228/LSE20180329070012_13586019/